Aclaris Therapeutics price to sales ratio ACRS

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 67.2×
8-year median: 21.2×
Against its 8-year history: 71st; percentile: 0 is its lowest day, 100 its highest
8-year range: 2.2× to 195×
Peer median: 1.5×

Aclaris Therapeutics' price to sales ratio is 67.2× as of Oct 23, 2026.

That is above its 8-year median of 21.2×, higher than on 71% of days in the last 8 years.

Over that time it ranged from 2.2× in Aug 2019 to 195× in Aug 2022.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	67.2×	18.0×	115×
2025	20.9×	5.9×	22.4×
2024	7.2×	2.3×	10.7×
2023	3.5×	2.8×	50.9×
2022	44.7×	42.8×	195×
2021	130×	42.1×	191×
2020	46.3×	2.9×	54.5×
2019	5.1×	2.2×	42.1×
2018	40.3×	38.5×	85.2×

Against its peers

Companies in Drug Manufacturers - General nearest Aclaris Therapeutics' size, closest first, today.

Company	Price to sales ratio
ACRSAclaris Therapeutics	67.2×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
ARVNArvinas	1.5×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
NATRNatures Sunshine Products	0.4×
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Aclaris Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.